| Generic name | Crizotinib |
| Brand name(s), other common name(s) | Xalkori® |
| Drug type | Kinase inhibitor |
| How the drug is given | By mouth |
Indications and Usage
Crizotinib is FDA approved for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
Limitations of Use: The safety and efficacy of Xalkori have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.
Side effects needing medical attention
The most common adverse reactions in patients with ALCL, excluding laboratory abnormalities, are diarrhea, vomiting, nausea, vision disorder, headache, musculoskeletal pain, stomatitis, fatigue, decreased appetite, fever, abdominal pain, cough, and pruritus. Grade 3-4 laboratory abnormalities are neutropenia, lymphopenia, and thrombocytopenia.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.